BRAF and melanoma: Heinzerling et al. evaluated BRAF mutation heterogeneity between tumor samples isolated from the primary tumor and those from metastases from patients with melanoma.50 In this study, the tumors were not under the selection pressure of a BRAF inhibitor because tumor samples were collected prior to the availability of BRAF inhibitor therapy.